BOSTON, US: There seems to be a link between two serious medical disorders. Globally, millions of individuals suffer from multiple sclerosis (MS), a condition that attacks the body’s central nervous system, while hundreds of millions of people suffer from depression, a mood illness with crippling symptoms.
Nearly three times as many MS patients experience depression as people without the disease. Before a recent study by researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, addressed this knowledge gap, it was unknown how and why MS and depression are connected. The team aimed to localise MS depression by comparing lesion sites in the brains of MS patients, drawing on a recent work that described a depression circuit in the brain.
The findings of the study were published in Nature Mental Health.
“If we want to find specific locations of brain damage that cause specific symptoms, it sometimes works, but only for simpler brain functions like vision or movement. When it comes functions like those associated with depression, it’s not that simple,” said corresponding author Shan Siddiqi, MD, an assistant professor of psychiatry at Harvard Medical School and director of psychiatric neuromodulation research at Brigham and Women’s Center for Brain Circuit Therapeutics. “When a patient has lesions all over the brain, we used to assume they were unrelated to depression, because they seemed so disconnected. But with lesion network mapping (LNM), we can see even when lesions don’t directly overlap with each other, they may overlap with the same circuit.”
While many clinicians have assumed that certain lesions were more likely to cause depression in MS, it had never been proven before, and neither had a specific pattern that connected those lesions. LNM is fundamental in seeing such a pattern for depression, since LNM allows researchers to envision networks of connectivity rather than just solitary sites of damage. In a 2021 study, the same Brigham team identified a common brain circuit — which connected seemingly disparate brain lesion sites — for patients that experienced depression after stroke or penetrating head trauma. The team set out to determine if MS lesions and depression could be connected through this new circuit.
To conduct their study, Siddiqi, co-first author Isaiah Kletenik, MD, and co-authors relied on a database of 281 patients with MS which has been curated by Drs. Tanuja Chitnis, Bonnie Glanz, and Rohit Bakshi of the Brigham Multiple Sclerosis Center in the Department of Neurology. Dr. Charles Guttmann and his team in the Brigham Center for Neurological Imaging in the Department of Radiology developed a virtual laboratory environment that allows systematic collection and analysis of MRI and clinical data, which greatly facilitated this work. Drs. Guttmann and Bakshi also collaborated to develop an automated lesion detection and outlining protocol, allowing the researchers to locate lesions with relative ease. For each patient, estimated connectivity between lesion locations was determined using a connectome database, a large-scale wiring diagram of the human brain which has been made possible by initiatives such at the Human Connectome Project. Using the connectome database and LNM, the team found significant functional connectivity between MS lesion locations and their a priori depression circuit. Additionally, the data-driven circuit for MS depression showed similar topography to the a priori depression circuit. Together, these findings provide novel localization of MS depression.
While offering important insight into MS depression, the study had a few key limitations. All patient history was unknown, meaning, on top of other potentially unknown histories, some patients may have had depression prior to MS. Additionally, the sample size — albeit the largest so-far of its kind — was limited. The next step is clinical trials, as this novel localization of MS depression enables a host of possibilities for therapeutic targeting.
“The more we know about the connectivity of lesions that cause symptoms, the better our ability to target an ideal stimulation site for those symptoms,” said Siddiqi. “We’ve already shown the success of targeting our a priori depression circuit in other patients. Now that we’ve shown that the circuit can be applied to MS depression, we should be able to find a treatment target for these patients, too.”
Nearly three times as many MS patients experience depression as people without the disease. Before a recent study by researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, addressed this knowledge gap, it was unknown how and why MS and depression are connected. The team aimed to localise MS depression by comparing lesion sites in the brains of MS patients, drawing on a recent work that described a depression circuit in the brain.
The findings of the study were published in Nature Mental Health.
“If we want to find specific locations of brain damage that cause specific symptoms, it sometimes works, but only for simpler brain functions like vision or movement. When it comes functions like those associated with depression, it’s not that simple,” said corresponding author Shan Siddiqi, MD, an assistant professor of psychiatry at Harvard Medical School and director of psychiatric neuromodulation research at Brigham and Women’s Center for Brain Circuit Therapeutics. “When a patient has lesions all over the brain, we used to assume they were unrelated to depression, because they seemed so disconnected. But with lesion network mapping (LNM), we can see even when lesions don’t directly overlap with each other, they may overlap with the same circuit.”
While many clinicians have assumed that certain lesions were more likely to cause depression in MS, it had never been proven before, and neither had a specific pattern that connected those lesions. LNM is fundamental in seeing such a pattern for depression, since LNM allows researchers to envision networks of connectivity rather than just solitary sites of damage. In a 2021 study, the same Brigham team identified a common brain circuit — which connected seemingly disparate brain lesion sites — for patients that experienced depression after stroke or penetrating head trauma. The team set out to determine if MS lesions and depression could be connected through this new circuit.
To conduct their study, Siddiqi, co-first author Isaiah Kletenik, MD, and co-authors relied on a database of 281 patients with MS which has been curated by Drs. Tanuja Chitnis, Bonnie Glanz, and Rohit Bakshi of the Brigham Multiple Sclerosis Center in the Department of Neurology. Dr. Charles Guttmann and his team in the Brigham Center for Neurological Imaging in the Department of Radiology developed a virtual laboratory environment that allows systematic collection and analysis of MRI and clinical data, which greatly facilitated this work. Drs. Guttmann and Bakshi also collaborated to develop an automated lesion detection and outlining protocol, allowing the researchers to locate lesions with relative ease. For each patient, estimated connectivity between lesion locations was determined using a connectome database, a large-scale wiring diagram of the human brain which has been made possible by initiatives such at the Human Connectome Project. Using the connectome database and LNM, the team found significant functional connectivity between MS lesion locations and their a priori depression circuit. Additionally, the data-driven circuit for MS depression showed similar topography to the a priori depression circuit. Together, these findings provide novel localization of MS depression.
While offering important insight into MS depression, the study had a few key limitations. All patient history was unknown, meaning, on top of other potentially unknown histories, some patients may have had depression prior to MS. Additionally, the sample size — albeit the largest so-far of its kind — was limited. The next step is clinical trials, as this novel localization of MS depression enables a host of possibilities for therapeutic targeting.
“The more we know about the connectivity of lesions that cause symptoms, the better our ability to target an ideal stimulation site for those symptoms,” said Siddiqi. “We’ve already shown the success of targeting our a priori depression circuit in other patients. Now that we’ve shown that the circuit can be applied to MS depression, we should be able to find a treatment target for these patients, too.”
